1
|
Morimont L, Didembourg M, Bouvy C, Jost M, Taziaux M, Oligschlager Y, van Rooijen M, Gaspard U, Foidart JM, Douxfils J. Low thrombin generation in postmenopausal women using estetrol. Climacteric 2024; 27:193-201. [PMID: 38241059 DOI: 10.1080/13697137.2023.2292066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2023] [Accepted: 12/01/2023] [Indexed: 03/13/2024]
Abstract
OBJECTIVE Estetrol (E4) represents a novel estrogen of interest to relieve vasomotor symptoms. E4 activates the nuclear estrogen receptor α (ERα) but antagonizes the estradiol ERα-dependent membrane-initiated steroid signaling pathway. The distinct pharmacological properties of E4 could explain its low impact on hemostasis. This study aimed to assess the effect of E4 on coagulation in postmenopausal women, using the thrombin generation assay (TGA). METHODS Data were collected from a multicenter, randomized, placebo-controlled, dose-finding study in postmenopausal women (NCT02834312). Oral E4 (2.5 mg, n = 42; 5 mg, n = 29; 10 mg, n = 34; or 15 mg, n = 32) or placebo (n = 31) was administered daily for 12 weeks. Thrombograms and TGA parameters were extracted for each subject at baseline and after 12 weeks of treatment. RESULTS After 12 weeks of treatment, all treatment groups showed a mean thrombogram (±95% confidence interval [CI] of the mean) within the reference ranges, that is, the 2.5th-97.5th percentile of all baseline thrombograms (n = 168), as well as for TGA parameters. CONCLUSIONS The intake of E4 15 mg for 12 weeks led to significant but not clinically relevant changes compared to baseline as the mean values (±95% CI of the mean) remained within reference ranges, demonstrating a neutral profile of this estrogen on hemostasis.
Collapse
Affiliation(s)
- L Morimont
- QUALIresearch, Qualiblood s.a, Namur, Belgium
- Clinical Pharmacology and Toxicology Research Unit (CPRU), Namur Research Institute for LIfe Sciences (NARILIS), Faculty of Medicine, University of Namur, Namur, Belgium
| | - M Didembourg
- Clinical Pharmacology and Toxicology Research Unit (CPRU), Namur Research Institute for LIfe Sciences (NARILIS), Faculty of Medicine, University of Namur, Namur, Belgium
| | - C Bouvy
- QUALIresearch, Qualiblood s.a, Namur, Belgium
| | - M Jost
- Estetra SRL, An affiliate Company of Mithra Pharmaceuticals, Liège, Belgium
| | - M Taziaux
- Estetra SRL, An affiliate Company of Mithra Pharmaceuticals, Liège, Belgium
| | - Y Oligschlager
- Estetra SRL, An affiliate Company of Mithra Pharmaceuticals, Liège, Belgium
| | - M van Rooijen
- Estetra SRL, An affiliate Company of Mithra Pharmaceuticals, Liège, Belgium
| | - U Gaspard
- Department of Obstetrics and Gynecology, University of Liège, Liège, Belgium
| | - J-M Foidart
- Estetra SRL, An affiliate Company of Mithra Pharmaceuticals, Liège, Belgium
- Clinical Sciences Department, Faculty of Medicine, University of Liège, Liège, Belgium
| | - J Douxfils
- QUALIresearch, Qualiblood s.a, Namur, Belgium
- Clinical Pharmacology and Toxicology Research Unit (CPRU), Namur Research Institute for LIfe Sciences (NARILIS), Faculty of Medicine, University of Namur, Namur, Belgium
- Department of Biological Hematology, Centre Hospitalier Universitaire Clermont-Ferrand, Hôpital Estaing, Clermont-Ferrand, France
| |
Collapse
|
2
|
Douxfils J, Gaspard U, Taziaux M, Jost M, Bouvy C, Lobo RA, Utian WH, Foidart JM. Impact of estetrol (E4) on hemostasis, metabolism and bone turnover in postmenopausal women. Climacteric 2023; 26:55-63. [PMID: 36399023 DOI: 10.1080/13697137.2022.2139599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
OBJECTIVE This study aimed to determine the effects of estetrol (E4) on hemostasis, lipids, carbohydrate metabolism and bone turnover in postmenopausal women. METHODS This study was a multicenter, randomized, double-blind placebo-controlled phase 2 trial. Participants (n = 180, age 43-64 years) received E4 2.5 mg, 5 mg, 10 mg and 15 mg or placebo once daily for 12 weeks. Changes from baseline at week 12 were evaluated versus placebo for hemostasis parameters, sex hormone binding globulin (SHBG), lipids, carbohydrate metabolism and bone markers. RESULTS Changes for hemostasis parameters were minimal with a small increase only in the normalized activated protein C sensitivity ratio in the E4 15 mg group versus placebo. SHBG increased in the E4 5 mg, 10 mg and 15 mg groups versus placebo. High-density lipoprotein cholesterol increased in all E4 groups; changes were not consistent for other lipids. Significant decreases versus placebo were seen for insulin resistance (E4 10 mg group), hemoglobin A1c (E4 15 mg group) and type 1 collagen C-terminal telopeptide (E4 10 mg and 15 mg groups). Small decreases in osteocalcin in the E4 5 mg, 10 mg and 15 mg groups were significant versus the increase observed in placebo. CONCLUSION E4 had limited impact on hemostasis and potentially beneficial effects on lipids, carbohydrate metabolism and bone turnover.
Collapse
Affiliation(s)
- J Douxfils
- Department of Pharmacy, Namur Thrombosis and Hemostasis Center, University of Namur, Namur, Belgium.,QUALIblood s.a, Namur, Belgium
| | - U Gaspard
- Department of Obstetrics and Gynecology, University of Liège, Liège, Belgium
| | - M Taziaux
- Estetra SRL, an affiliate company of Mithra Pharmaceuticals, Liège, Belgium
| | - M Jost
- Estetra SRL, an affiliate company of Mithra Pharmaceuticals, Liège, Belgium
| | - C Bouvy
- QUALIblood s.a, Namur, Belgium
| | - R A Lobo
- Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY, USA
| | - W H Utian
- Case Western Reserve Medical School, Cleveland, OH, USA
| | - J-M Foidart
- Department of Obstetrics and Gynecology, University of Liège, Liège, Belgium.,Estetra SRL, an affiliate company of Mithra Pharmaceuticals, Liège, Belgium
| |
Collapse
|
3
|
Grobet M, Capelle X, Willems T, Triffaux JM, Gaspard U, Kridelka F. [«I am not pregnant !» About denial of pregnancy…]. Rev Med Liege 2020; 75:484-488. [PMID: 32779894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
The term «denial of pregnancy», although used in current medical practice since 1970, does not yet have a universal definition. The literature allows to define it as «the non-recognition of a pregnancy beyond the first trimester, which can last until delivery and cover it». The changes related to pregnancy are biologically reduced or incorrectly perceived or even ignored. Although often wrongly considered as a rare phenomenon, the literature describes it as having a prevalence of 2 to 3 cases per 1.000 viable deliveries. This case report associated with a short review of the literature aims to optimise the clinician awareness, leading to the diagnosis as well as the potential perinatal consequences linked to this phenomenon.
Collapse
Affiliation(s)
- M Grobet
- Faculté de Médecine, ULiège, Belgique
| | - X Capelle
- Service de Gynécologie-Obstétrique, CHU Liège, Belgique
| | - T Willems
- Service de Gynécologie-Obstétrique, Grand Hôpital de Charleroi, Belgique
| | | | - U Gaspard
- Service de Gynécologie-Obstétrique, CHU Liège, Belgique
| | - F Kridelka
- Service de Gynécologie-Obstétrique, CHU Liège, Belgique
| |
Collapse
|
4
|
Slomian J, Reginster JY, Gaspard U, Streel S, Beaudart C, Appelboom G, Buckinx F, Bruyère O. Exploring the interest in and the usage of the internet among patients eligible for osteoporosis screening. Calcif Tissue Int 2015; 96:518-26. [PMID: 25837844 DOI: 10.1007/s00223-015-9987-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/27/2014] [Accepted: 03/18/2015] [Indexed: 10/23/2022]
Abstract
The aim of this study was to evaluate the interest in the Internet and its usage for health-related issues among people eligible for osteoporosis screening. Self-administered questionnaires have been distributed to subjects who were screened for osteoporosis and to menopausal women. 177 patients have responded to the survey (64.5 ± 10.1 years, 88.1% of women). There are 78.5% of Internet users. Among them, 67.2% said searching information about their health and 74.5% said using the Internet for this purpose. All respondents attributed an average score, out of 10, of 5.7 ± 2.3 regarding the reliability of information that they could find on the Internet. The use of the Internet differs significantly depending on age: those who use the Internet are younger (62.1 ± 8.91 years) than those who do not use it (73.3 ± 9.42 years). The socioeconomic status also has an impact on the Internet use: Internet users have a higher education, are more professionally active and have a higher net monthly household income compared to the group of non-users. Even if age and socioeconomic status appear to be determining factors in the use of the Internet for the search of health information in patients eligible for osteoporosis screening, almost 75% of the study population use the Internet for this purpose. Action to promote health through an Internet platform must therefore take these parameters into account.
Collapse
Affiliation(s)
- J Slomian
- Support Unit in Epidemiology and Biostatistics, University of Liège, Avenue de l'Hôpital 3 - CHU B23, 4000, Liège, Belgium,
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Gaspard U, Verguts J, Simon P, Depypere H, Merckx M, Loquet P, Walravens F, Firquet A, Poppe W, Leunen M, Donders G, Squifflet J, Grandjean P. [The use of intrauterine device in nulliparous over 18 years: a Belgian consensus]. J Pharm Belg 2014:28-35. [PMID: 25562925] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Under the presidency of prof. H. Depypere (UZ Ghent) and Prof. P. Simon (ULB Erasme) a Belgian panel of thirteen experts (gynecologists, representatives of universities and scientific associations for gynecology-obstetrics) reached a consensus on the use of intrauterine systems, both copper IUDs as hormone IUDs, in nultiparous women.
Collapse
|
6
|
Pintiaux A, Gaspard U, Nisolle M. [Zoely, a combined oral contraceptive, monophasic pill containing estradiol and nomegestrol acetate]. Rev Med Liege 2012; 67:152-156. [PMID: 22611833] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
A new combined oral contraceptive called Zoely has just been marketed in Belgium. It contains nomegestrol acetate, a progestin known for its high contraceptive reliability based on its antigonadotropic power and long half-life. This progestin is associated with estradiol and Zoely is devoid of ethinyl estradiol, which is the usual component of the majority of combined oral contraceptives and is primarily responsible for thrombotic side effects of the pill. The compositon and type of regimen of this new oral contraceptive contribute to its efficacy and excellent clinical tolerance.
Collapse
|
7
|
Desreux J, Gaspard U, Bleret V, Van Cauwenberge JR, Thille A, Herman P, Lifrange E. [Breast cancer in Belgium: why are we the first in Europe?]. Rev Med Liege 2011; 66:231-237. [PMID: 21826953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Breast cancer incidence in Belgium is on the top of European countries, with 9.697 new cases in 2008 and 106/100.000 women/year. The explanation of this high incidence in our country is probably the accumulation of risk factors (many of them are linked to lifestyle), and the impact of screening and registration of cases. The relative impact of each of theses factors is less clear because we don't have powerful statistical studies. Belgium is slightly above the European mean for breast cancer mortality, with 19,4/100.000 women/year and an all stages 15-year survival of 75%. Breast cancers are responsible for around 3% of all-cause mortality in Belgian women. This article discusses the causes of this high Belgian incidence and of current decrease of incidence in western countries, and reviews known and less known risk factors of breast cancers, with a special focus on menopause hormonal treatments.
Collapse
Affiliation(s)
- J Desreux
- Service de Sénologie, CHU de Liège, Belgique.
| | | | | | | | | | | | | |
Collapse
|
8
|
Scheen AJ, Gaspard U. [Medication of the month. Femoston Low (0.5 mg estradiol plus 2.5 mg dydrogesterone) for menopausal hormonal replacement therapy]. Rev Med Liege 2011; 66:209-214. [PMID: 21638840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Femoston Low is a hormone replacement therapy that combines low dosages of steroids, i.e. 0.5 mg of estradiol and 2.5 mg of dydrogesterone. This oral preparation should be taken continuously to treat climacteric symptoms in menopausal women. Femoston Low is in agreement with the recent recommendations for menopausal hormone replacement therapy, which give the preference to low dosage therapy whenever possible. The goals are to potentially minimize the risk of breast cancer, the danger of venous or arterial thrombosis and the glucose and lipid metabolic disturbances. Nevertheless, the preparation should efficaciously oppose to endometrial hyperplasia and yield a high degree of amenorrhea.
Collapse
|
9
|
Gaspard U, Kridelka F. [Ulipristal acetate: an emergency contraception extended to 5 days using a progesterone receptor modulator (Ellaone)]. Rev Med Liege 2010; 65:700-705. [PMID: 21287767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Emergency contraception is a second chance for prevention of pregnancy after unprotected intercourse. Hormonal emergency contraception with levonorgestrel 1.5 mg, only provides an effective contraception from 0 to 72 hours after intercourse with decreasing effectiveness as time elapses. It was accordingly mandatory to develop an alternative approach with a stable contraceptive efficacy and good tolerance for 5 days, knowing additionally that the estimated lifespan of sperm in the female genital tract is about 5 days. In comparative studies bearing on more than 3000 young women, the progesterone receptor modulator (PRM) ulipristal acetate, a progesterone antagonist (taken in a single dose of 30 mg), or levonorgestrel (1.5 mg) were administered. Results indicated that the PRM was as effective as levonorgestrel, or even more, kept a stable efficacy for 120 hours after an unprotected intercourse, and was well tolerated. This establishes ulipristal acetate as the new standard for hormonal emergency contraception.
Collapse
Affiliation(s)
- U Gaspard
- CHU de Liege, Policlinique Universitaire, Belgique.
| | | |
Collapse
|
10
|
Gaspard U, Pintiaux A, Kridelka F. [Medication of the month. A new combined oral contraceptive containing estradiol valerate and dienogest (Qlaira)]. Rev Med Liege 2010; 65:706-713. [PMID: 21287768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
In combined oral contraception (OC), a drastic reduction of both ethinylestradiol and androgenic progestins mostly derived from 19 NOR testosterone, allowed to moderately reduce the adverse impact of classical combined pills on metabolism and circulation (both arterial and venous). However, the marked hepatic action of ethinylestradiol, even in small dosages, lessens the expected risk reduction. For the first time, an OC has been developed, which contains estradiol valerate (with reduced hepatic action because of lack of a 17alpha ethinyl group) with dienogest, a 19 NOR testosterone-derived nonandrogenic progestin, which powerfully inhibits endometrial proliferation. Thanks to a dynamic modulation of estrogen and progestin doses (26 active days + 2 placebo days), an adequate contraceptive effectiveness, a good cycle control and drug tolerance are achieved, similar to those obtained with a classical low-dose OC. Recent data indicate that this new combination reduces the usually observed metabolic impact. An adequate cycle control (with 20% amenorrhea) is achieved for the first time with estradiol valerate + progestin,, in opposition with prior catastrophic results with other formulations containing 17beta-estradiol. A second combination containing estradiol + nomegestrol acetate (monophasic, 24 active days + 4 placebo days) is under study and seems also to yield promising results. Of course, in-depth study of metabolic and vascular effects of these new combinations is mandatory - and ongoing.
Collapse
Affiliation(s)
- U Gaspard
- Service universitaire de Gynécologie Obstétrique CHR Citadelle, Liège, Belgique.
| | | | | |
Collapse
|
11
|
Gaspard U. [Prevention of coronary heart disease by early postmenopausal hormone therapy: new supporting data]. J Gynecol Obstet Biol Reprod (Paris) 2008; 37:340-345. [PMID: 18249506 DOI: 10.1016/j.jgyn.2007.12.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/20/2007] [Revised: 10/12/2007] [Accepted: 12/05/2007] [Indexed: 05/25/2023]
Abstract
The important controversy concerning the potential beneficial, neutral or unfavourable effect of estrogens or estrogen plus progestin on the risk of coronary heart disease in postmenopausal women is beginning to settle down. Reanalysis of large observational and randomized trials according to age and years since menopause and recent additional studies allow to positively state that postmenopausal hormone therapy - and particularly estrogens alone - is safe and effective. For instance, in the Women's Health Initiative study, provided hormone therapy is initiated within 10 years since menopause, a reduction of the risk of coronary heart disease by 12 to 52% according to the use of estrogen plus progestin or estrogen alone, respectively, is observed versus placebo use. Global mortality is also reduced by 30% with both hormone therapies. This favourable effect is not observed when treatment is initiated in older postmenopausal women. These important and reassuring data should encourage regulatory authorities to reassess clinical recommendations in that prospect.
Collapse
Affiliation(s)
- U Gaspard
- Service de gynécologie-obstétrique, CHU du Sart-Tilman B-35, université de Liège, B-4000 Liège-1, Belgique.
| |
Collapse
|
12
|
Delcominette S, Gaspard U. [Female sexual dysfunction and postmenopausal androgen therapy]. Rev Med Liege 2008; 63:23-30. [PMID: 18303682] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Female sexual dysfunction is essentially multifactorial and its therapeutic management is accordingly diversified. However, after natural menopause or, even more, surgical menopause, age, climacteric syndrome, progressive loss of endogenous androgens, all facilitate the occurrence of the Hypoactive Sexual Desire Disorder (HSDD), defined by loss of libido and sexual responsiveness leading to sexually related personal distress. In that prospect, administration of varied medications with androgenic properties has been tried in addition to postmenopausal hormone therapy. Type, dosages, routes of administration of androgens are adapted toward minimizing side effects inasmuch as long-term safety of androgens is not yet clearly established. Recent randomized controlled studies appear very promising in terms of efficacy and safety, at least when androgen therapy is limited to 6-12 months in case of HSDD.
Collapse
|
13
|
Pincemail J, Vanbelle S, Gaspard U, Collette G, Haleng J, Cheramy-Bien JP, Charlier C, Chapelle JP, Giet D, Albert A, Limet R, Defraigne JO. Effect of different contraceptive methods on the oxidative stress status in women aged 40 48 years from the ELAN study in the province of Liege, Belgium. Hum Reprod 2007; 22:2335-43. [PMID: 17584753 DOI: 10.1093/humrep/dem146] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Oxidative stress is associated with the development of several disorders including cardiovascular disease and cancer. Among conditions known to influence oxidative stress, the use of oral contraception (OC) in women has been a matter of ongoing discussion. METHODS A total of 897 eligible and healthy volunteers were recruited from among the patients of 50 general practitioners participating in the ELAN study (Etude Liégeoise sur les ANtioxydants). A subsample consisting of 209 women aged 40-48 years was studied for a comprehensive oxidative stress status (OSS), including the analysis of antioxidants, trace elements and three markers of oxidative damage to lipids. Among 209 subsample, 49 (23%) were OC users (OCU), 119 (57%) non-contraception users (NCU) and 41 (20%) were intrauterine (hormonal and copper) devices users (IUD). RESULTS After adjustment for smoking, systolic and diastolic blood pressure and BMI (or waist circumference), a marked and significant increase in lipid peroxides was observed among OCU women when compared with NCU and IUD users. A cut-off value of 660 microM in lipid peroxides allowed the discrimination of OCU from the two other groups. In contrast, no difference was observed in the plasma concentration of both oxidized low-density lipoprotein (LDL) and their related antibodies. The increased level in lipid peroxides was strongly related to higher concentrations of copper (r < 0.84; P < 0.0001, cut-off value 1.2 mg/l). When compared with NCU and IUD users, plasma antioxidant defences were significantly altered in OCU women as shown by lower levels of beta-carotene (decrease of 39%; P < 0.01) and gamma-tocopherol (decrease by 22%; P < 0.01). In contrast, higher concentrations of selenium (increased by 11.8%; P < 0.01) were observed in OCU women. Blood concentrations of vitamin C, alpha-tocopherol and zinc were unaffected by OC use. CONCLUSIONS The intake of OC significantly increases the lipid peroxidation in women aged 40-48 years. This may represent a potential cardiovascular risk factor for these women.
Collapse
Affiliation(s)
- J Pincemail
- Department of Cardiovascular Surgery, University of Liège, CHU Sart Tilman, 4000 Liège, Belgium.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Gaspard U, Dubois M. [Therapeutic progress in gynecology: functional approaches]. Rev Med Liege 2007; 62:423-7. [PMID: 17725217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
Over the last ten years, progress in evidence-based medicine coupled with technological breakthroughs and introduction of new drugs have deeply changed the management of our patients. In the field of hormone therapy, lower dosages of estrogens and new progestins have increased tolerance and non-contraceptive benefits of oral contraceptives, while lower-doses, new progestins, new routes of administration have optimized the benefit/risk balance for the treatment of menopause. About 500,000 cycles of IVF are performed worldwide each year, optimizing male and female fertility, with less multiple pregnancies, and use of new recombinant gonadotropin, LHRH agonists/antagonists, new ovarian tissue cryopreservation techniques, etc...
Collapse
Affiliation(s)
- U Gaspard
- Service de Gynécologie, CHU Sart Tilman et Notre-Dame des Bruyères, Liège, Belgique
| | | |
Collapse
|
15
|
Herman P, Lifrange E, Nisolle M, Kridelka F, Nervo P, Gaspard U. [Therapeutic progress in gynecology: organic diseases]. Rev Med Liege 2007; 62:414-22. [PMID: 17725216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
Over the last ten years, progress in evidence-based medicine coupled with technological and surgical breakthroughs have deeply changed the management of our patients. Uterine bleeding is the first cause of gynaecological consultation and the intrauterine progestin delivery system as well as new hysteroscopic procedures have optimized the therapeutic approach to this problem. Introduction of magnetic resonance imaging and interventional procedures have improved breast disease diagnosis and management; likewise sentinel node localization, introduction of aromatase and growth factors inhibitors, new radiotherapy procedures and pharmacogenomics, have helped to ameliorate breast cancer treatment. Pelvic surgery has been switching more and more towards laparoscopic procedures not only in the field of benign lesions (eg endometriosis), of surgery of prolapse and incontinence with new prosthetic materials, but also for an improved management of gynaecological cancers.
Collapse
Affiliation(s)
- P Herman
- Service de Gynécologie CHU Sart Tilman, Liège, Belgique
| | | | | | | | | | | |
Collapse
|
16
|
Piérard GE, Piérard-Franchimont C, Quatresooz P, Kridelka F, Gaspard U. [Can we sort out from the jumble about oral contraceptives and skin cancers?]. Rev Med Liege 2007; 62:463-6. [PMID: 17725223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
Skin contains various hormonal receptors, particularly those for estrogens, progesterone and androgens. Steroid hormones of oral contraceptives affect the skin, in particular the control of the cell cycle, DNA replication, apoptosis and other cellular functions. Some estrogen-responsive pathways have the potential to promote tumor development. The question of whether oral contraceptives increase the risk for the development of skin cancer, particularly melanoma, remains an area of concern. There is some evidence that steroid hormones present in oral contraceptives do not significantly increase the risk of developing skin cancer when estrogen exposure is not excessive.
Collapse
|
17
|
Dricot JF, Dubois M, Gaspard U, Salmon C, Herman P. [Image of the month. An intrauterine pregnancy after endometrial ablation]. Rev Med Liege 2007; 62:5-6. [PMID: 17343121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
|
18
|
Van den Brûle F, Freyens A, Gaspard U. [Management of Chlamydia tracomatis pelvic infection]. Rev Med Liege 2006; 61:433-41. [PMID: 16910273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
The infection by Chlamydia trachomatis is a serious infection that affects the male and female tractus, and that induces complications such as infertility and extrauterine pregnancy. The antibiotic treatment needed must necessarily reach the intracellular milieu to be efficient enough to eradicate the infection.
Collapse
Affiliation(s)
- F Van den Brûle
- Service de Gynécologie-Obstétrique, CHU Sart Tilman et Notre-Dame des Bruyères, Université de Liège.
| | | | | |
Collapse
|
19
|
Abstract
Adenomyosis is a frequent entity, with difficult diagnosis, often obtained by pathological analysis performed after hysterectomy. This condition can cause abnormal uterine bleeding and dysmenorrhea, frequent reasons for consultation and hysterectomy. The development of ultrasonographic and magnetic resonance imaging techniques allow preoperative diagnosis. They also permit the use of hysteroscopic techniques for conservative uterine surgery, and have brought diagnosis and management of this disease to the front of the scene. This article reviews the pathological description of the disease, its epidemiology, clinical presentations, useful and necessary explorations, etiopathogeny and available therapies.
Collapse
Affiliation(s)
- O Wéry
- Service de Gynécologie, CHU Sart-Tilman
| | | | | | | |
Collapse
|
20
|
Abstract
A gender perspective is indispensable for a full understanding of aging. Menopause is a turning point in women's lives. In addition to the effects of chronological aging, sunlight exposure, and other environmental and endogenous stimuli, the climacteric appears to exert some dramatic consequences on skin biology and aspect. The epidermis may become xerotic and exhibit altered functions. The dermis thins out and its elasticity decreases in concert with the decline in bone mass. The skin microcirculation is impaired. These aspects are some of the better worked-out changes of the climacteric, which in turn seem to be stabilized or in part reversible with hormone replacement therapy (HRT). The HRT effect on menopause consequences on hair growth and sebum production is less impressive. This review summarizes some important impacts of the climacteric on skin, and highlights the benefits of HRT that may influence cosmetic dermatology.
Collapse
Affiliation(s)
- Pascale Quatresooz
- Department of Dermatopathology, University Hospital of Liège, Liège, Belgium
| | | | | | | |
Collapse
|
21
|
Thirion L, Piérard-Franchimont C, Arrese JE, Quatresooz P, Gaspard U, Piérard GE. [The skin and menopause]. Rev Med Liege 2006; 61:159-62. [PMID: 16681001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/09/2023]
Abstract
The estrogen deficit occurring at menopause manifests itself under various modalities in the diverse organs and their functions. Skin does not escape this global involutive process. In addition to the effects of chronological ageing, sunlight exposure and other environmental and endogenous stimuli, the climacteric appears to exert some dramatic consequences on skin biology and aspect. The epidermis, its adnexae and the dermis are altered by this process. The epidermis may become xerotic and exhibits altered functions. The dermis thins out and its elasticity decreases in concert with the decline in bone mass. The skin microcirculation is impaired. These aspects are some of the better-worked out skin climacteric changes of which in turn seem to be stabilized or in part reversible with hormone replacement therapy (HRT).
Collapse
Affiliation(s)
- L Thirion
- Service de Dermatopathologie CHR hutois, Huy
| | | | | | | | | | | |
Collapse
|
22
|
Gaspard U, Van Den Brûle F. [Extended oestrogen-progestin contraceptive regimens: towards a contraception without menses]. Rev Med Liege 2006; 61:23-6. [PMID: 16491544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
Women's attitude concerning menstruations is changing towards achieving extended cycles with few or even suppressed menses, in view of the unpleasant perimenstrual bleeding, pain and discomfort pattern that may accompany menstruation. Use of combined oral estrogen-progestin contraception in extended "cycles" of 3, 6 and 12 or more months is now under active study. Extended cycle contraception is abided by a better compliance than conventional cycle contraception with ensuing optimized contraceptive effectiveness. Hypothetically, transdermal or transvaginal combined contraception could be used in extended cycles. Tolerance is comparable for both methods and unpredicted bleeding, initially more frequent during long cycle treatment tends to become less frequent after about 6 months a compared with conventional cycles. Usual safety parameters appear to be similar under both contraceptive modalities. Comfort and well being brought by extended cycle use (5 to 10 times fewer days of bloating or perimenstrual pain) allow to estimate that, according to acceptability studies, 10 to 40 percent of women of reproductive age would currently choose extended cycle contraception.
Collapse
Affiliation(s)
- U Gaspard
- Maître de Recherches FNRS, Service de Gynécologie, Centre Hospitalier Universitaire de Liège
| | | |
Collapse
|
23
|
Lebrun Y, Goffioul V, Herman P, Gaspard U, Van Den Brûle F. [Image of the month: a development and symptomatic tubular pregnancy]. Rev Med Liege 2005; 60:837-8. [PMID: 16402525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Affiliation(s)
- Y Lebrun
- Service associé, Chargé de Cours adjoint, CHU Sart Tilman, B-4000 Liège
| | | | | | | | | |
Collapse
|
24
|
van den Brûle F, Bouché MJ, Wauters O, Herman P, Lebrun Y, Gaspard U. [Image of the month: ulcerated mammary cancer]. Rev Med Liege 2005; 60:689-90. [PMID: 16267890] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
|
25
|
van den Brûle F, Gaspard U. [Contraception in young diabetic women]. Rev Med Liege 2005; 60:335-7. [PMID: 16035290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
Contraception of the diabetic patient is an important matter. It allows to plan adequately the pregnancies, should respect carbohydrate metabolism and should consider the risk of diabetic complications. This review article describes the contraceptive techniques for diabetic patients.
Collapse
Affiliation(s)
- F van den Brûle
- Maître de Recherches du FNRS, Service de Gynécologie-Obstétrique, CHU Sart Tilman et Notre-Dame des Bruyères, B-4000 Liège, Belgique.
| | | |
Collapse
|
26
|
Gaspard U, van den Brûle F. [Menopause-related risks and hormone therapy in diabetic women]. Rev Med Liege 2005; 60:586-9. [PMID: 16035332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
Prevalence of diabetes mellitus (types 1 and 2) in postmenopausal women is about 10-20% according to age. It can be associated with a metabolic syndrome in about 60% of cases, thereby severely increasing cardiovascular risk (among others) in these women. Estrogen or estrogen-progestin replacement therapy does not usually impair diabetes control. It will be submitted to the same indications/contraindications, in relation with the risk/benefit balance, as for all other postmenopausal women. However, increased risks inherent to diabetic subjects concerning metabolism, coagulation/hemostasis, and cardiovascular disease, should be considered. Therefore, estrogen in minimal effective dosages, eventually by transdermal route, as well as metabolically neutral progestins near to progesterone should be preferred. In case of pre-existing or occurring vascular problems, a careful approach or even suppression of replacement therapy should prevail.
Collapse
Affiliation(s)
- U Gaspard
- Service de Gynécologie, ULg, CHU Sart Tilman, Liège.
| | | |
Collapse
|
27
|
van den Brûle F, Wauters O, Gaspard U. [Image of the month. Diagnosis of micropolycystic ovary by transvaginal ultrasonography]. Rev Med Liege 2005; 60:133-4. [PMID: 15884693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Affiliation(s)
- F van den Brûle
- Service de Gynécologie, CHU Sart Tilman, B-4000 Liège, Belgique
| | | | | |
Collapse
|
28
|
Piérard L, Gaspard U, Baguet E, Limet R. [Replacement of the descending aorta sparing the aortic valve: the David's operation]. Rev Med Liege 2005; 60:141-3. [PMID: 15884696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Abstract
We report the case of an ascending aortic aneurysm involving the aortic root, with a functionally competent bicuspid aortic valve, treated by the David's operation. This operation allows to fix the aortic root pathology, whilst preserving the native aortic valve. The technical aspects, surgical indications, and potential benefits of this operation are reviewed.
Collapse
|
29
|
Gaspard U, Endrikat J, Desager JP, Buicu C, Gerlinger C, Heithecker R. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception 2004; 69:271-8. [PMID: 15033400 DOI: 10.1016/j.contraception.2003.11.003] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2003] [Revised: 10/24/2003] [Accepted: 11/07/2003] [Indexed: 12/21/2022]
Abstract
In this open-label, randomized study we compared the influence of a new oral contraceptive containing 30 microg ethinylestradiol and 3 mg drospirenone (EE + DRSP = Yasmin), with a reference preparation containing 30 microg ethinylestradiol and 150 microg desogestrel (EE + DSG = Marvelon) on the lipid profile. The primary target variables were total high-density lipoprotein (HDL) cholesterol, HDL2 cholesterol and low-density lipoprotein (LDL) cholesterol. These and additional lipid and lipoprotein fractions were measured at baseline and in the 3rd, 6th and 13th treatment cycles in a total of 50 volunteers, and also assessed after density gradient ultracentrifugation. A slight increase in mean total HDL cholesterol vs. baseline was found for the DRSP group (+12.8%) and the DSG group (+11.8%) after 13 treatment cycles. HDL2 cholesterol did not change remarkably in both groups. The mean LDL cholesterol values increased by 10.6% vs. baseline in the DSG group and remained nearly stable in the DRSP group (+1.8%). All measured values remained within the reference ranges. No statistically significant differences were found between the two treatment groups for those primary endpoints. A slight rise in mean total cholesterol was found for all cycles after the initiation of treatment. The mean increase after 1 year of treatment was approximately 8% in both treatment groups. Mean triglyceride levels increased for both treatment groups without leaving the reference range. The increase for total triglycerides was +73.6 % in the DRSP group and +61.3% in DSG group. For total phospholipids, an increase of +13.6% (DRSP) and +18.5% (DSG) over 13 cycles was measured. The apolipoproteins Apo A-I, Apo A-II and Apo B increased slightly more during DRSP treatment than during DSG treatment. The reduction of Apo E was similar in both groups. Lipoprotein (a) remained stable in the DRSP group, whereas it increased by +10.8% in the DSG group. In conclusion, the combined low-dose oral contraceptive Yasmin, with 30 microg ethinylestradiol and 3 mg of the novel progestogen drospirenone, as well as the reference preparation, had little impact on the lipid profile. While both preparations displayed a favorable lipid profile with increased total HDL cholesterol, the antiandrogenic or missing androgenic activity of Yasmin may be regarded as responsible for the stable LDL cholesterol levels. As a result, the ratio of total HDL:LDL was increased, a pattern that is usually considered clinically beneficial with respect to cardiovascular disease risk.
Collapse
Affiliation(s)
- U Gaspard
- Department of Gynecology, University of Liege, Sart Tilman University Hospital, Liège, Belgium.
| | | | | | | | | | | |
Collapse
|
30
|
Gaspard U, Van den Brûle F. [Medication of the month. Angeliq: new hormonal therapy of menopause, with antialdosterone and antiandrogenic properties]. Rev Med Liege 2004; 59:162-6. [PMID: 15139405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
Following American randomised controlled epidemiologic studies (HERS, WHI), regulatory authorities have advised that postmenopausal hormone therapy, using minimal effective dosages, is indicated for the first line treatment of climacteric symptoms during a limited, and problem-related period of time, and for second line prevention of osteoporosis when a non-hormonal treatment cannot be used. Observation of a discrete increase in cardiovascular and breast cancer risk in hormone users currently appears to partly justify this rather strict attitude. We report here results of studies concerning a new continuous combination regimen (Angeliq), associating a "half-dose" estrogen (estradiol 1 mg/d) with potentially less thrombogenic impact than a standard (2 mg) dose, and the new progestin drospirenone (2 mg/d). The latter demonstrates a high level of endometrial safety as well as unique antialdosterone properties (reduction of symptoms related to water retention; potential cardioprotective effects) and consistent antiandrogenic properties, useful for both metabolic and clinical issues. Accordingly, Angeliq constitutes a new therapeutic approach, in good agreement with updated guidelines related to hormone replacement therapy.
Collapse
|
31
|
van den Brûle F, Gaspard U. [Risk of thromboembolism in contraception and hormone substitution: an update and recommendations]. J Pharm Belg 2004; 59:38-40. [PMID: 15129579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
Venous and arterial thromboembolism events are unfrequent but classical complications of sex steroid therapy, in contraception and menopause. The relative risks induced by these treatments have recently highlighted by the general press, in particular for the 2nd and 3rd generation progestins in oral contraception. In this article, we will review the risks of venous and arterial thromboembolism in patients treated with oral contraception or postmenopausal hormone replacement therapy. Practical guidelines will be defined.
Collapse
Affiliation(s)
- F van den Brûle
- Service de Gynécologie, CHU Sart Tilman, B-4000 Liège, Belgique.
| | | |
Collapse
|
32
|
van den Brûle F, Gaspard U. [Body mass changes at menopause: impact of therapeutic strategies]. Rev Med Liege 2003; 58:734-40. [PMID: 14978847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
Weight gain constitutes a worry for perimenopausal patients. Current understanding of the problem indicates that age constitutes the most important factor, whereas menopause contributes to the development of android obesity. Hygyenodietetic counseling allows to reduce or even prevent these problems. Finally, hormone replacement therapy does not induce weight gain: it rather contributes to reduce central adipose deposition and improves the risk profile of menopausal patients, in relation to the nature and metabolic profile of the prescribed molecules.
Collapse
|
33
|
Gaspard U. [Medication of the month. Evra: first contraceptive transdermal patch]. Rev Med Liege 2003; 58:709-12. [PMID: 14748201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/28/2023]
Abstract
Evra is a transdermal patch releasing 20 micrograms of ethinylestradiol and 150 micrograms of norelgestromin/day during one week. The circulating levels of steroids attained are of similar amplitude though steadier than after intake of an oral combined low-dose estrogen-progestin pill. The transdermal method is user-friendly and is abided by a high degree of acceptability, and a low level of skin irritability. Its contraceptive effectiveness is similar to that conferred by oral contraceptives except if the treated woman is over 90 kg, in which case Evra should not be prescribed. Cycle control is excellent and similar to that of triphasic pills. Adverse effects and tolerance are comparable to those described with low-dose oral contraceptives with a slight estrogen dominance. Lipid and glucose metabolism as well as coagulation are influenced in the same way. Gastrointestinal disturbances (nausea, vomiting) do not prevent the efficacy of the transdermal patch. Compliance with Evra is significantly higher than with oral combined contraceptives--a major point for an effective contraception. Accordingly, Evra constitutes an useful addition to the current array of contraceptive methods.
Collapse
MESH Headings
- Administration, Cutaneous
- Adult
- Contraception/methods
- Contraceptives, Oral
- Contraceptives, Oral, Combined/administration & dosage
- Contraceptives, Oral, Combined/adverse effects
- Contraceptives, Oral, Combined/pharmacokinetics
- Contraceptives, Oral, Combined/pharmacology
- Drug Combinations
- Ethisterone/analogs & derivatives
- Female
- Glucose/metabolism
- Humans
- Lipid Metabolism
- Menstrual Cycle/drug effects
- Nausea/chemically induced
- Norgestrel/analogs & derivatives
- Oximes
- Vomiting/chemically induced
Collapse
Affiliation(s)
- U Gaspard
- Service de Gynécologie, CHU du Sart Tilman-Université de Liège
| |
Collapse
|
34
|
Gaspard U. [What scientific and clinical findings will result from the controlled trial "Women's Health Initiative"?]. Bull Mem Acad R Med Belg 2003; 158:133-41; discussion 141-5. [PMID: 12852099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/03/2023]
Abstract
The Women's Health Initiative Study is the first large randomized controlled trial for primary prevention, comparing the beneficial or adverse effects of an oral continuous-combined regimen of conjugated estrogens + medroxyprogesterone acetate, vs placebo in late postmenopausal women. This study brings evidence for an absence of preventive cardiovascular effects of hormone replacement therapy (HRT), shows for the first time a small increase in risk for coronary disease, and confirms a small increased risk for invasive breast cancer from four-five years of treatment on, a reduction of risk of colorectal cancer and osteoporotic fractures, and a moderate increase in other already known cardiovascular risks during HRT, such as venous thromboembolism and stroke. Although this study has inherent limitations and may be criticised, and the observed risks are restricted, it forces the physician to better respect known contra-indications (a.o. vascular) to HRT, to carefully weigh the benefit/risk balance of the patients, shorten HRT administration (4-5 years?), use minimal effective hormone dosages, preferably by non-oral route, and change for new compounds with more selective estrogenic action, which are under development.
Collapse
|
35
|
van den Brûle F, Gaspard U. [Image of the month. Ultrasonic diagnosis of uterine septum]. Rev Med Liege 2003; 58:523. [PMID: 14626642] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
|
36
|
Pintiaux A, Van den Brûle F, Foidart JM, Gaspard U. [Hormone replacement therapy one year after the results of the Women's Health Initiative]. Rev Med Liege 2003; 58:572-5. [PMID: 14626652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
The currently reported data concerning the large WHI randomized controlled trial compare the impact of continuous combined conjugated estrogens + medroxyprogesterone acetate vs placebo in postmenopausal women. These results appear largely pessimistic. After 5.2 years of hormone replacement, an excess of coronary heart disease, cerebrovascular disease, venous thromboembolism, breast cancer incidence and extension, mild cognitive impairment and dementia is recorded. By contrast, osteoporotic fracture risk and colorectal cancer are decreased during hormone replacement. Accordingly, this hormonal treatment can no longer be recommended on a long term basis, except after extensive risk-benefit balance evaluation. It should no longer be prescribed for prevention of chronic diseases. It remains indicated during 4-5 years for relief of vasomotor symptoms, genital atrophy and, potentially, for some aspects of quality of life. HRT should probably be prescribed in minimal-effective dosages; new regimens, routes of administration, new compounds and associations should be envisaged in order to avoid cardiovascular or breast problems. However these new approaches ask for thorough validation studies.
Collapse
Affiliation(s)
- A Pintiaux
- Université de Liège, Département de gynécologie-obstétrique
| | | | | | | |
Collapse
|
37
|
Gaspard U, Scheen A, Endrikat J, Buicu C, Lefebvre P, Gerlinger C, Heithecker R. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. Contraception 2003; 67:423-9. [PMID: 12814810 DOI: 10.1016/s0010-7824(02)00537-1] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
In this open-label, randomized study we compared the influence of a new oral contraceptive containing 30 microg ethinylestradiol and 3 mg drospirenone (Yasmin) with a reference preparation containing 30 microg ethinylestradiol and 150 microg desogestrel (Marvelon) on variables of carbohydrate metabolism by means of oral glucose tolerance tests at baseline and in the 6th and 13th treatment cycle. The mean levels of fasting glucose and insulin were similar at baseline and after 13 treatment cycles, whereas C-peptide and free fatty acid levels decreased slightly in both groups. All blood glucose and insulin values measured in the oral glucose tolerance tests were within normal ranges, despite a slight increase in the mean areas under the curves of 0-3 h [AUCs (0-3 h)] of both variables from baseline to treatment cycle 13. Differences between both treatments were not statistically significant. The mean AUCs (0-3 h) for C-peptide were not markedly changed in any treatment group. Free fatty acid levels decreased by 42% in the drospirenone group and increased by 48.9% in the desogestrel group, in terms of means of individual changes. Both preparations were well tolerated and equally efficacious regarding contraception and cycle control. The mean body weight was slightly decreased in most cycles during treatment with the drospirenone combination, as compared to baseline, while it was slightly increased versus baseline in all cycles during treatment with the desogestrel combination. The combination with drospirenone had less impact on blood pressure than the combination with desogestrel. In conclusion, Yasmin, a combined low-dose oral contraceptive with 30 microg ethinylestradiol and 3 mg of the novel progestogen drospirenone, as well as the reference Marvelon, containing 30 microg ethinylestradiol and 150 microg desogestrel had little impact on carbohydrate metabolism when used for 1 year. The observed changes were small and not suggestive of a clinically relevant deterioration of carbohydrate metabolism.
Collapse
Affiliation(s)
- U Gaspard
- Department of Gynecology, University of Liege, Sart Tilman University Hospital, Liège, Belgium.
| | | | | | | | | | | | | |
Collapse
|
38
|
Lifrange E, Bleret V, Desreux J, Dondelinger RF, Foidart JM, Gaspard U, Herman P, Van Cauwenberge JR, Colin C. [Benefits and limitations of mammography]. Rev Med Liege 2003; 58:331-7. [PMID: 12940126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/21/2023]
Abstract
The literature on screening mammography provides ample opportunity for doubt (the sceptics) and dogma (the screening zealots), and can be interpreted to prove both benefit and harm. The benefit of mammography screening, if any, is modest and the balance between beneficial (potentially, a 20% relative reduction in breast cancer mortality with no significant benefit on all-cause mortality) and harmful (physical and psychological morbidity related to the 15-40% missed cancers and the 80-90% false-positive diagnoses) effects is still delicate. The mammogram alone is a modest weapon. Concurrent clinical breast examination is mandatory. Women that are concerned about breast cancer should be fully informed of the potential benefits and risks of screening mammography. These women should benefit from mammography with concurrent clinical breast examination, and possible whole-breast ultrasound in heterogeneously dense and extremely dense breast patterns.
Collapse
|
39
|
Abstract
BACKGROUND Controversy still exists about the breast carcinogenic properties in humans of environmental xenoestrogens (organochlorines), justifying new investigations. AIMS To compare the blood levels of total dichlorodiphenyltrichloroethane (DDT) and hexachlorobenzene (HCB) in samples collected at the time of breast cancer discovery, in order to avoid the potential consequences of body weight change (after chemotherapy or radiotherapy) on the pesticide residue levels. METHODS Blood levels of HCB and total DDT (we calculated total DDT concentrations by adding all DDT and DDE isomers) were compared in 159 women with breast cancer and 250 presumably healthy controls. Risk of breast cancer associated with organochlorine concentration was evaluated. RESULTS Mean levels of total DDT and HCB were significantly higher for breast cancer patients than for controls. No differences in serum levels of total DDT or HCB were found between oestrogen receptor positive and oestrogen receptor negative patients with breast cancer. CONCLUSIONS These results add to the growing evidence that certain persistent pollutants may occur in higher concentrations in blood samples from breast cancer patients than controls.
Collapse
Affiliation(s)
- C Charlier
- Clinical Toxicology Laboratory, Sart Tilman University Hospital, University of Liege, 4000 Liege, Belgium.
| | | | | | | | | | | | | |
Collapse
|
40
|
van den Brûle F, Lifrange E, Pintiaux A, Foidart JM, Gaspard U. [Postmenopausal hormone replacement therapy and breast cancer risk: an update]. Rev Med Liege 2003; 58:254-60. [PMID: 12868330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 03/03/2023]
Abstract
Numerous studies have examined the risk of breast cancer in patients with postmenopausal hormone substitution. Most of these studies are retrospective, and a few recent studies are prospective. The observed results present with weak variations from baseline and major heterogeneity. Some studies highlight a slightly increased relative risk of breast cancer. A reanalysis of 51 studies demonstrates a relative risk of 1.35 for developing breast cancer during hormone substitution, with a 2.3% increased risk per year of use. Recently, the results of the WHI study have shown a slight increase of some risks of disease, including breast cancer (relative risk, 1.26). These results have induced the interruption of one of the 3 arms of the study (that of the patients treated with an estrogen-progestin combination), and have provoked a new discussion about the benefits and risks associated with hormone substitution. These facts have been largely related and commented in the general press. In this article, we review the important studies concerning this topic.
Collapse
|
41
|
Gaspard U, van den Brûle F, Pintiaux A, Foidart JM. [Clinical study of the month. Benefit/risk balance of postmenopausal estrogen-progestin treatment in peril in the Women's Health Initiative study: practical attitude of the clinician]. Rev Med Liege 2002; 57:556-62. [PMID: 12405030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/27/2023]
Abstract
The Women's Health Initiative (WHI) is sponsored by the NIH. The study focuses on risk and benefits of strategies that could potentially reduce the incidence of heart disease, breast and colon cancer, and fractures in postmenopausal women. One arm of the study, a double-blind, placebo-controlled trial, looking at the effects of continuous combined estrogen-progestin regimen was stopped prematurely based on health risks which exceeded health benefits. The main reason for this decision was the increase in risk of invasive breast cancer, as well as a slight increase in the rate of myocardial infarction and stroke. In this paper, we inform our colleagues of the detailed results of the study. We comment on its limitation and discuss the new original observations. Finally, we integrate the others to previous world literature data that are confirmed by the WHI study. It is important for the individual prescribing practitioner to issue practical conclusions and therapeutic recommendations. The department of Obstetrics and Gynaecologic of the University of Liege, in agreement with the European Menopause Society and the International Menopause Society, is convinced that there is no alternative to the hormone replacement therapy for menopausal symptoms. We should stick to the traditional indications for hormones, namely vasomotor symptoms and osteoporosis. We should continue to recommend hormones for symptomatic women. One should realize that the risk for breast cancer appears only after several years of use, and the risk for cardiovascular events below age 60 is very small (the age of the patients was 63 at inclusion in the WHI study). We should encourage women to take the necessary measures for routine, periodic breast examinations (both manual, echographic and radiographic). Women who use HRT for more than 5 years should discuss the latest data of the WHI study with their physician, in order to consider their individual benefit-risk equation. Those who feel good on hormones and are fully satisfied with this treatment should learn of possible harm after long-term use. It is important to take into account the importance of quality of life. We should leave to the patient the final decision whether or not to continue the treatment. It is presently impossible to decide whether other estroprogestin associations, other administration routes and other molecules such as estradiol, natural progesterone or other progestins, SERMS and Tibolone could have an impact very different from that of the estroprogestin combination used in the WHI study. It is the duty of every physician to decide, from the complex epidemiological data obtained in the aged women (63-68 years) with a high cardiovascular risk in the WHI study, if it is possible or not in each individual case to recommend the initiation or pursue of an hormone replacement therapy.
Collapse
Affiliation(s)
- U Gaspard
- Département de Gynécologie-Obstétrique, l'Université de Liège
| | | | | | | |
Collapse
|
42
|
Gaspard U. [Pharma-Clinics. Medication of the month. Totelle Cycle: new sequential estrogen/progesterone regimen for hormone replacement therapy in menopause]. Rev Med Liege 2002; 57:408-12. [PMID: 12180037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/26/2023]
Abstract
Totelle Cycle is a sequential regimen containing 2 mg of oestradiol for 28 days associated with a new progestogen, trimegestone, from day 15 to 28. It is indicated for the treatment of climacteric symptoms and the prevention of post-menopausal bone loss. Trimegestone is a new 19-NOR progesterone derivative with an original activity profile, near to--but much more powerful than--progesterone itself, and devoid of androgenic, glucocorticoïd and oestrogenic activity. This particular profile confers to trimegestone its metabolic neutrality and concurs to the high degree of safety and tolerance observed in studies related to Totelle Cycle.
Collapse
Affiliation(s)
- U Gaspard
- Université de Liège, Service de Gynécologie, CHU Sart Tilman
| |
Collapse
|
43
|
van den Brûle F, Wéry O, Herman P, Gaspard U. [Towards better investigation of abnormal uterine bleeding and uterine pathologies]. Rev Med Liege 2002; 57:307-9. [PMID: 12143176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
Exploration of menometrorrhagia needs perfect imaging of the uterus and pathologic analysis in order to diagnose the endometrial pathologies responsible for abnormal uterine bleeding. We present here a clinical case typical for difficulties in the exploration of abnormal uterine bleeding, and discuss the diagnostical steps.
Collapse
|
44
|
Herman P, Gaspard U. [How I treat ... surgically benign uterine lesions in 2002]. Rev Med Liege 2002; 57:187-90. [PMID: 12073788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
For 20 years, pre-operative investigations have increasingly improved the gynaecological diagnosis, allowing to have an accurate idea on the size and the nature of the lesion to be treated when the matter is to carry out the surgical treatment. In the meantime, the gynaecological surgery has seen its endoscopic surgical techniques improved due to the development of these diagnostic techniques itself. The operative hysteroscopy allows to decrease considerably the amount of hysterectomies for benign lesions. The operative laparoscopy has become the first intended treatment for many pathologies. This latter allows performing either laparoscopic assisted vaginal hysterectomies or complete laparoscopic hysterectomies. On the other hand, even though these endoscopic techniques were developing, the vaginal hysterectomy strongly returned, in such a way that it became the dominating way, so that the rule is to perform abdominal hysterectomy only when it is impossible to carry out a low way hysterectomy. Consequently, the gynaecologist surgeon has to be capable, in 2002, to perform all these surgical techniques in order to offer to the patient the best treatment, matching as good as feasible according to the pathology to be treated and her anatomical status.
Collapse
|
45
|
Piérard GE, Piérard-Franchimont C, Vanderplaetsen S, Franchimont N, Gaspard U, Malaise M. Relationship between bone mass density and tensile strength of the skin in women. Eur J Clin Invest 2001; 31:731-5. [PMID: 11473575 DOI: 10.1046/j.1365-2362.2001.00841.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND Skin and bone may be affected similarly during the climacteric and during long-term corticotherapy. Little is known about the correlation between the respective alterations in bone mass density (BMD) and tensile strength of the skin. MATERIALS AND METHODS A total of 100 women aged 19-88 years, receiving, or not, hormone replenishment therapy or systemic corticosteroids, were enrolled in the study. Tensile strength of the inner forearm skin was measured using the suction method operated in both the steep and progressive-force application modes. BMD was measured by dual X-ray absorptiometry at the hip, femoral neck and lumbar spine. RESULTS Being heterogeneous, the population of volunteers yielded a wide range of BMD and cutaneous tensile strength values. However, significant correlations were found between BMD and tensile skin parameters. In particular, a positive correlation was yielded between the biological elasticity of skin and the BMD of the hip and femoral neck. CONCLUSION An overall correlation is shown between skin elasticity on a relatively sun-protected area and cortico-trabecular BMD.
Collapse
Affiliation(s)
- G E Piérard
- Department of Dermatopathology, University of Liège, Liège, Belgium.
| | | | | | | | | | | |
Collapse
|
46
|
Gaspard U, Buicu C, Creutz V. [Multiple benefits of physical exercise in menopausal women]. Rev Med Liege 2001; 56:219-22. [PMID: 11421156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
In postmenopausal women, metabolic and cardiovascular risks are increased not only because of aging but also in relation to estrogen deprivation, decreased physical activity and dietary changes. Accordingly, an increase in total fat mass and its intra-abdominal component, a decrease in lean body mass, an atherogenic dyslipidemia, decreased glucose tolerance, insulin resistance and an increase in procoagulant factors are ensuing, in a manner similar to the metabolic syndrome X and its accompanying risk for cardiovascular disease. Physical exercise concurs with an appropriate diet to weight loss, increases lean body mass and altogether energy expenditure, decreases total body fat mass and visceral fat, improves insulin sensitivity, reduces fibrinogenemia and optimizes hemodynamic parameters. Additionally, physical exercise contributes to protecting bone mass and may be associated with a decreased risk of estrogen-dependent breast and endometrial carcinomas at the postmenopause. In association with a balanced diet, and estrogen administration, physical exercise significantly contributes to metabolic fitness and decreased cardiovascular risk in postmenopausal women.
Collapse
Affiliation(s)
- U Gaspard
- Service de Gynécologie, CHU Sart Tilman
| | | | | |
Collapse
|
47
|
Piérard-Franchimont C, Gaspard U, Lacante P, Rhoa M, Slachmuylders P, Piérard GE. A quantitative biometrological assessment of acne and hormonal evaluation in young women using a triphasic low-dose oral contraceptive containing gestodene. EUR J CONTRACEP REPR 2000; 5:275-86. [PMID: 11245555 DOI: 10.1080/13625180008500405] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
OBJECTIVE To investigate the effect of a triphasic low-dose oral contraceptive pill containing gestodene on acne severity and hormone levels in young women over 13 menstrual cycles. METHODS A total of 33 subjects aged 16-25 years with moderate facial acne were enrolled in the study. The primary efficacy end-points used in the clinical assessment of acne were the overall severity and number of lesions, sebum secretion and superficial follicular biopsy. Both physicians and patients evaluated acne status. Blood levels of sex hormone binding globulin (SHBG), estradiol, progesterone and androgens were monitored. RESULTS By cycle 13, the total lesion count had been reduced by 80%. Physicians and patients assessed acne status in 90% and 95% of cases, respectively, as better or much better (p < 0.001). At the end of the study, SHBG levels had increased by 229% and total and free testosterone levels had decreased by 41% and 70%, respectively. CONCLUSION An oral contraceptive containing triphasic gestodene has a beneficial effect on the severity ofacne, decreases major circulating androgen levels and is well tolerated.
Collapse
|
48
|
Gaspard U, Buicu C, van den Brûle F. [New forms of hormonal contraception]. J Gynecol Obstet Biol Reprod (Paris) 2000; 29:288-91. [PMID: 10804374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
Among new forms of hormonal contraception, three interesting exemples are described with a high level of effectiveness and low dosage regimen that allow improved safety and tolerance: a very low-dose estrogen-progestogen combination of ethinylestradiol and gestodene for 24-day cyclical administration; a progestogen-alone subcutaneous implant containing etonogestrel; and a levonorgestrel-releasing intrauterine system. These preparations appear to be particularly interesting as they provide additional possibilities for individualizing contraceptive therapy.
Collapse
Affiliation(s)
- U Gaspard
- Service de Gynécologie, CHU Sart Tilman B 35, Université de Liège, 4000 Liège 1, Belgique
| | | | | |
Collapse
|
49
|
Mouchamps E, Gaspard U. [Change in sexual desire in the menopausal woman: a succinct evaluation]. J Gynecol Obstet Biol Reprod (Paris) 1999; 28:232-8. [PMID: 10456305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
Physicians or gynecologists, specifically in their general practice or in the setting of a menopause clinic, are more and more frequently confronted with sexual complaints of menopausal women. Among these, decline in sexual desire is probably the most usually reported. The first study to evaluate a potential relationship between sexual functioning and menopause was conducted by Hallström in 1977. Thereafter, a review of the literature was able to show that there is nearly a consensus regarding the role of estrogens in that condition. They effectively relieve vaginal atrophy and resulting dyspareunia. There is less agreement, however, regarding a direct effect of estrogens on more complex sexual behavior and motivation. When analyzing potential influence of sex hormones, estrogens may exert a positive effect on the quality of the sexual relationship whereas androgens can definitely increase sexual "motivation" including sexual desire. In spite of the potentially important part played by androgens as promoters of libido and in the maintenance of sexual functioning in men and women, the exact role of the hormonal treatment in releaving sexual complaints still remains controversial. In some women where decline of sexual desire can be reasonably attributed to menopause, androgens in non-masculinizing adequate dosages, can be effectively included in the postmenopausal hormone replacement regimen. However, etiology of diminished sexual motivation and desire is far from univocal particularly in the human being where psychological, social and cultural influences are endowed with a prominent importance. It is accordingly quite conspicuous that our sexual life is not reduced to hormonal fluctuations only. A short critical review of the literature devoted to the main aspects of changes of sexual desire associated with menopause is presented.
Collapse
Affiliation(s)
- E Mouchamps
- Centre de la Ménopause, CHU Sart Tilman, Liège, Belgique
| | | |
Collapse
|
50
|
Gaspard U, van den Brûle F. [Hormone replacement therapy: practical recommendations]. Rev Med Liege 1999; 54:481-8. [PMID: 10394250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Abstract
In addition to vasomotor symptoms, trophic and functional urogenital problems, postmenopause is characterized by an increased risk of osteoporosis, cardiovascular disease and cognitive problems. The goal of estrogen replacement therapy is to reduce these risks. Numerous therapeutic schemes are available and allow to reach a better acceptance of the treatment and, in some cases, to avoid uterine bleeding. The goal of this individual adaptation of the treatment is to obtain the best benefit/risk balance for each patient, with the best clinical tolerance, allowing to continue the treatment as long as possible. Moreover, new molecules proposed as monotherapies have been recently marketed. In this article, we will review the various modalities of hormone replacement therapy, their advantages and disadvantages, and contraindications.
Collapse
Affiliation(s)
- U Gaspard
- Service de Gynécologie, Université de Liège
| | | |
Collapse
|